New drug KP-001 tested for interactions with common meds
NCT ID NCT06821698
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study looked at how a new drug called KP-001 interacts with other medications in 38 healthy adults. The study measured how KP-001 affects the body's processing of rosuvastatin (a cholesterol drug) and caffeine, and how fluvoxamine (an antidepressant) affects KP-001 levels. The goal was to understand potential drug interactions, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KP-001
- What this could lead to
- If successful, this study could help determine safe dosing for KP-001 when taken with other common drugs.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels in the blood, not whether KP-001 works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Parexel International Early Phase Clinical Unit
Glendale, California, 91206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.